Trial Profile
RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis - RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RIFUND-MS
- 01 Aug 2022 Results assessing safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden published in the Lancet Neurology
- 11 Oct 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2019 Status changed from recruiting to active, no longer recruiting.